Global Monoclonal Antibodies Pipeline Insight 2015

Bharat Book Bureau provides the report, on “Global Monoclonal Antibodies Pipeline Insight 2015”. https://www.bharatbook.com/healthcare-market-research-reports-455244/global-monoclonal-antibodies-pipeline-insight.html This report,monoclonal antibodies have come to be known as highly valuable therapeutic agents.

5th Sep, 2015- Mumbai, India: Bharatbook.“Global Monoclonal Antibodies Pipeline Insight 2015”. This has been followed by an increasing number of other monoclonal antibodies, of which many were among the best-selling drugs across the globe.

Ever since the Nobel Prize was bestowed on the person who invented the technology which enabled the preparation of monoclonal antibodies in 1984, their use has considerably expanded far beyond the scientific realm. https://www.bharatbook.com/healthcare-market-research-reports-455244/global-monoclonal-antibodies-pipeline-insight.html Paul Ehrlich framed a hypothesis that a “magic bullet” could be developed with an objective of targeting selective diseases. With the introduction and development of hybridoma technology by Kohler and Milstein, this hypothesis has become a reality. These monoclonal antibodies have come to be known as highly valuable therapeutic agents. This technology rendered mAbs to be highly potential of specific associations with their targeted antigens.Muromonab-CD3 (Orthoclone OKT3; Ortho Biotech) was the first of these antibodies which was approved in 1986, in the prevention of acute transplant rejection. This has been followed by an increasing number of other monoclonal antibodies, of which many were among the best-selling drugs across the globe.

Utility of mAbs in therapeutic treatment have been widely accepted among physicians and patients across the globe. This could be attributed to their high specificity due to which only diseased cells are eliminated while normal cells are spared. Their ability to bind target is high because they are made by using single antigen giving them high...